Células-tronco mononucleares autólogas e proteína óssea morfogenética na cicatrização de defeitos tibiais experimentalmente induzidos em cães

Abstract

RESUMOAvaliou-se a utilização de células-tronco mononucleares (CTM) na cicatrização de defeito ósseo experimental como alternativa aos métodos convencionais, analisando-se o tempo de evolução cicatricial e a presença dessas células no tecido neoformado. Foram utilizados 18 cães, separados em três grupos (G) de seis, e de cada animal foram colhidas células da medula óssea (MO), contadas e analisadas para morfometria, por meio da contagem manual e mielograma. Um defeito ósseo tibial foi então criado cirurgicamente, e a lesão tratada com esponja de gelatina embebida em solução fisiológica (G1), esponja de gelatina embebida com aspirado de MO processado (G2) e esponja de gelatina embebida com aspirado de MO processado e proteína óssea morfogenética (rhBMP-2) (G3). A cicatrização foi então avaliada por estudos radiográficos, e a presença de CTM foi identificada por meio de marcadores nanocristais Qtracker, em microscopia com luz fluorescente, uma semana após a intervenção cirúrgica. Entre as células identificadas pelo marcador, foram encontradas células da linhagem óssea. As avaliações radiográficas demonstram crescimento ósseo acelerado nos animais de G2 e G3. Houve diferenças significativas entre o G1 e G3 em todos os tempos estudados, e entre G1 e G2 nos tempos de 30 e 45 dias. A utilização de CTM adultas suplementadas ou não com rhBMP-2 é alternativa favorável ao crescimento ósseo em defeitos experimentais agudos de tíbia de cães.Palavras-chave: cão, células-tronco, rhBMP-2, tíbia G1 and G3 dogs, in all studied periods; and between G1 and G2 animals ABSTRACT Mononuclear stem cells (MSC) were experimentally implanted in bone defect, as an alternative to the conventional methods, in order to evaluate the healing speed, and the presence of these cells in the newborn tissue. Bone marrow (BM) was collected from 18 dogs, and then counted and morphometrically analyzed by manual count and myelogram. The dogs were separated in three groups (G) of six animals each. A tibial bone defect was surgically made in each dog and the wound was treated with gelatin sponge and physiologic solution (G1), gelatin sponge and processed BM (G2), and gelatin sponge, processed BM, and rhBMP-2 (G3

Allogeneic mesenchymal stem cells and xenogenic platelet rich plasma, associated or not, in the repair of bone failures in rabbits with secondary osteoporosis

“…This biomaterial was sought because it did not trigger a local inflammatory response, whose degradation time does not interfere in the bone repair process and presents mechanical properties adequate for application in bone failures, as previously described in contemporary studies [23][24][25][26] .…”

Bone marrow stem cell applied in the canine veterinary clinics

“…Bone marrow stem cell applied in the canine veterinary clinics¹ Ingrid S. Gomes², Vanessa C. de Oliveira 3 to their origin such as, embryonic or adult (Oliveira 2008, Santos et al 2013. Additionally, several studies demonstrated, the regenerative function of these cells in damaged tissues (Narazaki & Cristante 2011, Ryu et al 2012, Bittencourt et al 2016, Stolfi et al 2016.…”

“…Adult stem cells can be isolated from various specialized tissues such as adipose tissue, bone marrow, tendon and cartilage (Colomé et al 2008, Oliveira et al 2010, Santos et al 2013. Consequently, the bone marrow stem cell (BMSC), from all the other tissues that have stem cells in Fig.1.…”

“…(Friedenstein et al 1974, Tharasanit et al 2011, Rici et al 2012, Kim et al 2013, Hu et al 2014 postnatal life, is the most studied, having two lines of stem cells: hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC) (Bittencourt et al 2006, BydlowskI et al 2009, Narazaki & Cristante 2011 (Fig.1 and 2). Furthermore, BMSC is the main source of stem cells, because of its easy isolation, and more than one to six millions of mesenchymal or/and hematopoietic stem cell can be isolated, cultured and applied without problem from one isolation (Oliveira et al 2010, Ryu et al 2012, Bittencourt et al 2016, Stolfi et al 2016.…”

“…Furthermore, such as stem cell characteristics and the potential benefits bring a new possibility in the treatment of congenital, degenerative, vascular, traumatic, and iatrogenic conditions (Hamzé et al 2009, Oliveira et al 2010). Thus, this cellular type is being widely used in researches because they do not present ethical barriers due to the ease of obtaining them and still to be used in autologous transplants, less probability of immunological rejection and the need of cellular inventory, since they are apparently inexhaustible (Castro-Silva et al 2010).…”